Conclusion
We have presented the first 450K DNA methylation array assessment of
women with PCOS compared at initial diagnosis to women with PCOS who
later developed diabetes. Despite the limitations of a small sample
study, we have identified multiple loci of differential DNA methylation
between these clinical phenotypes. We suggest that DNA methylation holds
exciting potential for identifying clinically-usable prognostic
biomarkers that may help identify women likely to develop diabetes at an
early stage where lifestyle interventions may be effective in reducing
risks of diabetes and other complications of PCOS.